Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00441376 · ClinicalTrials.gov registry record · Phase 1
A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver
A Phase 1 study, sponsored by Imunon.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00441376 is a Phase 1 study that has completed, run by Imunon. The registered enrollment target is 30 participants.
The verdict
NCT00441376, a Phase 1 study, has completed, sponsored by Imunon.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of ThermoDox when used in combination with radiofrequency ablation (RFA) in the treatment of primary and metastatic tumors of the liver.
Interventions
- DRUG ThermoDox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00441376
The ClinicalTrials.gov registry entry for NCT00441376 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Imunon, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ThermoDox is the first listed.
NCT00441376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00441376 about?
NCT00441376 is a clinical study titled "A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver". The purpose of this study is to determine the maximum tolerated dose (MTD) of ThermoDox when used in combination with radiofrequency ablation (RFA) in the treatment of primary and metastatic tumors of the liver.
What is the current status of trial NCT00441376?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2007-02. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00441376?
The interventions under investigation include: ThermoDox (DRUG).
Who is sponsoring clinical trial NCT00441376?
This trial is sponsored by Imunon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.